Today in Focus: RVMD

Trading Services I Use in my Trading:

StockAnalysis.com - I’ve been using Stock Analysis as an affordable but reliable method of looking at New and Upcoming IPOs, Earnings Calendars and most notably KPIs (Key Performance Indicators). Stock Analysis allows you to view the KPIs for many companies with up to date metrics and segments that you can cross reference against Earnings Results. This is incredibly important when understanding what metrics move a stock. At $65 per year it’s a no brainer. They’ve given me a discount code if you use IRISHBORNINVESTOR they will give you another 10% Off.

Market Condition: Market above all MAs. VIX trying to surge, Stocks Following through

Commentary: The market disregarded the overnight Trump drama with Iran. So far at least. VIX is strong this morning so monitoring that. The three stocks I’m watching this morning are Biotechs. I am very partial to a Biotech day especially when the market is red.

Earnings season kicking off this week. Plenty of opportunities likely.

The three I’m looking at are RVMD, ALLO and IDYA. First of all RVMD is a really big catalyst. IDYA is also an excellent catalyst and ALLO is probably the least of the three. I’m watching all three because ALLO despite having the weakest catalyst is moving the best and has a great chart. I’ve outlined the details below on RVMD. For what it’s worth I think maybe ALLO is going too far pre market and so far IDYA isn’t getting any volume.

In Play

RVMD:  One of the Biggest Biotech Catalysts in Several Years.

Key Metrics RVMD: Industry Group: Biotechnology, Market Cap: 25.72B, Float: 172.25M, Short Interest: 8.95%, Days to Cover: 6.11, Sales Y/Y TTM: -100.00%, EPS Y/Y TTM: -65.84%, Earnings: Feb 25 AMC, Exchange: NASDAQ

Catalyst: Announced positive topline results from RASolute 302, a global, randomized, controlled Phase 3 trial of daraxonrasib The headline OS result in the ITT population: 13.2 months vs. 6.7 months for chemotherapy, HR 0.40, p<0.0001 — a near-doubling of median OS, representing one of the most dramatic survival benefits seen in second-line PDAC in the modern era.

This is a transformative result for cancer patients.

My Biotech X Sentiment feed is really excited by this and I take note of that. Chart is certainly not neglected long term but still good consolidation since last move. Weekly since IPO has plenty of room to move.

"These results represent a potentially transformative advance for patients and underscore daraxonrasib's potential to redefine the treatment landscape." — Mark A. Goldsmith, CEO

"We believe these results firmly validate our pioneering approach to targeting common RAS-addicted cancers through RAS(ON) inhibition... [reflecting] more than 15 years of investment in groundbreaking scientific research." — Mark A. Goldsmith, CEO

"I believe that this new approach is a very important advance for the field that I expect will be practice-changing for physicians." — Brian M. Wolpin, MD, Principal Investigator (Harvard/Dana-Farber)

Current Positions: FSLY, DELL, SWBI, TH, NVDA

Delayed Reaction Watchlist (TradingView Link)

SGML - B/O

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}